Related Experiment Video
Updated: Jan 19, 2026
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Prevention of drug-related complications in cystic fibrosis
Renske van der Meer1, Daan J Touw2, Harry G M Heijerman3
1Department of Pulmonology, Haga Teaching Hospital, The Hague.
Purpose Of Review:
Due to continuous development of new drugs and better treatment strategies, survival of patients with cystic fibrosis has changed dramatically. Recently, targeted therapy of cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become available. Despite these promising developments, treatment of this complex multiorgan disease constitutes a high and variable amount of other drugs. Complications of pharmacotherapeutic treatment are, therefore, expected to become more prevalent. This gives cause to review drug-related side effects in this new era in cystic fibrosis treatment.
Recent Findings:
We will discuss cystic fibrosis-related pharmacotherapies with a focus on indication of treatment, side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity. Many recent publications about pharmacotherapy in cystic fibrosis, focus on antifungal therapy and CFTR modulators. We will give an overview of the most important studies.
Summary:
With increased life expectancy which is, in part, because of better treatment options, the burden of pharmacotherapy in cystic fibrosis patients will increase. This has a high impact on quality of life as pharmacotherapy is time consuming and may cause side effects. Therefore, it is very important to be aware of possible pharmacotherapy-related side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity.
Insights
New cystic fibrosis treatments improve survival but increase drug side effects. This review examines pharmacotherapies, focusing on managing drug-related complications and toxicity in cystic fibrosis patients.
Area of Science:
- Pulmonology
- Pharmacology
- Medical Genetics
Background:
- Cystic fibrosis (CF) patient survival has significantly improved due to advancements in drug development and treatment strategies.
- The advent of targeted therapies, such as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, marks a new era in CF management.
- Despite progress, CF remains a complex multiorgan disease requiring extensive pharmacotherapy, leading to a higher incidence of treatment-related complications.
Purpose of the Study:
- To review drug-related side effects in cystic fibrosis patients in the context of modern therapeutic advancements.
- To provide an overview of current pharmacotherapies for CF, emphasizing indications, side effects, and drug interactions.
- To highlight the importance of monitoring and preventing drug-induced toxicity in the evolving landscape of CF treatment.
Main Methods:
- Literature review focusing on recent publications regarding pharmacotherapy in cystic fibrosis.
- Analysis of studies on antifungal therapies and CFTR modulators.
- Discussion of drug indications, adverse effects, drug-drug interactions, and toxicity management strategies.
Main Results:
- Increased life expectancy in CF patients necessitates a greater pharmacotherapeutic burden.
- Pharmacotherapy significantly impacts patients' quality of life due to time commitment and potential side effects.
- Emerging treatments like CFTR modulators require careful consideration of their side effect profiles and interactions.
Conclusions:
- Awareness of potential pharmacotherapy-related side effects and complications is crucial for improving CF patient care.
- Effective management strategies for drug-induced toxicity and drug-drug interactions are essential.
- Ongoing research and review of pharmacotherapies are vital to optimize treatment outcomes and quality of life for individuals with cystic fibrosis.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:56Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
02:48Preparation of Artificial Sputum Medium to Emulate Cystic Fibrosis Lung Sputum Ex Vivo